These press releases are for business and financial media.
-
- 05 June 2002
- ASTRAZENECA RECEIVES FDA 'APPROVABLE' LETTER FOR CRESTOR™ AstraZeneca today confirms that it has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for 'Crestor' (rosuvastatin). The Company is reviewing its contents, and has no further comment at this time.
-
- 24 May 2002
- ASTRAZENECA APPOINTS NEW R&D LEADERSHIP TEAM - R&D Director to Retire AstraZeneca today announced the appointment of Dr. Martin Nicklasson as Executive Vice President, Development, with responsibility for global drug development and Dr. Jan Lundberg, Executive Vice President, Discovery Research, responsible for all global discovery programmes. Both Dr. Nicklasson and Dr. Lundberg will join the company's Senior Executive Team and report to the Chief Executive, Tom McKillop. The appointments will take effect immediately following the planned retirement of Dr.Claes Wilhelmsson
-
- 21 May 2002
- ASTRAZENECA ANNOUNCES RESULTS FOR IRESSA ™ (ZD1839) IN ADVANCED HEAD AND NECK CANCER AstraZeneca today announced data from the first Phase II trial of 'Iressa' in patients with recurrent, advanced squamous cell cancer of the head and neck, whose disease had progressed following radiation and/or chemotherapy, at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, Florida.
-
- 20 May 2002
- Iressa ™ Study Results Confirm Efficacy in Advanced Non-small Cell Lung Cancer AstraZeneca announced today that the final phase II results from the pivotal 'Iressa' IDEAL ('Iressa' Dose Evaluation in Advanced Lung Cancer) 1 and 2 studies presented at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, Florida, confirm 'Iressa' as an effective, potential new treatment approach, with a favourable tolerability profile for many patients with advanced non-small cell lung cancer (NSCLC). Additional data on 'Iressa' in patients with recurrent, advanced squamous
-
- 16 May 2002
- ASTRAZENECA AND SHIONOGI TO CO - MARKET CRESTOR™ – A NEW CHOLESTEROL LOWERING TREATMENT – IN JAPAN AstraZeneca and Shionogi & Co. Ltd. today announced an agreement to co-market CRESTOR™, a new treatment for dyslipidaemia, in Japan.
-
- 06 May 2002
- CRESTOR™ DATA AT WORLD CONGRESS OF CARDIOLOGY REINFORCE STRONG PRODUCT PROFILE Data were presented from two comparative studies involving a total of nearly 1,000 patients with hypercholesterolaemia. In both studies, changes in LDL-C levels (a major risk-factor for the development of CHD) and achievement of ATP-III LDL-C goals were assessed after a 12-week treatment period in patients receiving ‘Crestor’ 5 or 10mg compared with patients receiving pravastatin 20mg or simvastatin 20mg. The two studies were planned to enable the data to be analysed together.
-
- 01 May 2002
- PHARMACEUTICAL INDUSTRY LEADERS ELECTED FELLOWS OF ACADEMY OF MEDICAL SCIENCES Dr. Tom McKillop, Chief Executive of AstraZeneca, and Dr. Barry Furr, Chief Scientist and Head of Project Evaluation for AstraZeneca, have been elected Fellows of the Academy of Medical Sciences, a member of the influential grouping of UK national Academies, and are now entitled to use the designation FMedSci.
-
- 26 April 2002
- ASTRAZENECA RECEIVES FDA APPROVAL FOR FASLODEX - A NEW TYPE OF BREAST CANCER TREATMENT AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its new breast cancer drug 'Faslodex' for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antioestrogen therapy, (e.g. tamoxifen).
-
- 25 April 2002
- ASTRAZENECA PLC ANNOUNCES THE RESULTS OF THE POLLS TAKEN AT ITS ANNUAL GENERAL MEETING ON 25 APRIL 2002 AstraZeneca PLC announces the results of the polls taken at its Annual General Meeting today in respect of Items 9, 10 and 11 on the Agenda, as follows:
-
- 25 April 2002
- ASTRAZENECA PLC FIRST QUARTER RESULTS 2002 Download the narrative and the figures
-
- 24 April 2002
- ASTRAZENECA WINS LOSEC® PATENT CASE IN CANADA The Appeal Division of the Federal Court of Canada, has ruled in favour of AstraZeneca in litigation between AstraZeneca and RhoxalPharma Inc. under the Patented Medicines (Notice Of Compliance) Regulations.
-
- 15 April 2002
- ARIMIDEX RECEIVES FDA PRIORITY REVIEW FOR EARLY BREAST CANCER INDICATION AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has granted a six-month Priority Review Status to the supplemental new drug application (sNDA) for Arimidex in the adjuvant treatment of early breast cancer in postmenopausal women. AstraZeneca filed the sNDA for Arimidex with the FDA on March 4, 2002, through a ‘fast track’ submission process. Priority Review Status is granted for new drugs or indications that represent a significant improvement in efficacy or safety over existing
-
- 08 April 2002
- ARIMIDEX SUBMITTED FOR EARLY BREAST CANCER LICENCE EXTENSION IN EUROPE AstraZeneca announced today that it has filed for a licence extension for Arimidex, for the treatment of postmenopausal women with early-stage breast cancer, via the European Union (EU) Mutual Recognition Procedure, with the United Kingdom as reference member state. Arimidex is already licensed worldwide for use in postmenopausal women with advanced disease.
-
- 18 March 2002
- ASTRAZENECA PLC: BOARD APPOINTMENTS AND NOMINATIONS AstraZeneca PLC announced today:
-
- 13 March 2002
- FIFTY UNDERGRADUATE STUDENTS AT 23 UNIVERSITIES TO BENEFIT FROM ASTRAZENECA BURSARY PROGRAMME - £200,000 BOOST FOR CHEMISTRY EDUCATION IN UNITED KINGDOM AstraZeneca announced today a bursary programme worth at least £200,000 for students working toward a first degree in chemistry. Financial support, in the amount of £1,000 each year, will be provided to 50 students starting their studies in October 2002 at universities across the UK.
-
- 06 March 2002
- ASTRAZENECA TO SEEK LEAVE TO APPEAL OMEPRAZOLE PATENT DECISION IN UK COURT AstraZeneca today announced that it will seek leave to appeal against a decision by the Patents Court of the High Court of Justice’s Chancery Division in London that two of its formulation patents for omeprazole, the active ingredient in Losec, are invalid following legal challenges by two UK-based generic pharmaceutical companies.
-
- 04 March 2002
- ASTRAZENECA INVESTS $66 MILLION IN A NEW NEXIUM PRODUCTION FACILITY IN SÖDERTÄLJE, SWEDEN AstraZeneca is investing $66 million in a new production facility for Nexium Intravenous (IV) at one of its major production sites in Södertälje, Sweden. The capital expenditure provides a new state of the art facility for production of Nexium vials. It also incorporates essential infrastructure to support the manufacturing operations.
-
- 04 March 2002
- ASTRAZENECA PUBLIC OFFER TO PURCHASE REMAINING SHARES IN ASTRAZENECA PHARMA INDIA LTD AstraZeneca PLC today announced that its subsidiary Astra Pharmaceuticals AB is to make a voluntary public offer in India to purchase the 43.5% of shares in AstraZeneca Pharma India Limited, which it does not already own.
-
- 20 February 2002
- ASTRAZENECA RECEIVES FDA PRIORITY REVIEW FOR CASODEX 150 MG FOR THE TREATMENT OF EARLY STAGE PROSTATE CANCER AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has granted a six-month priority review for the Supplemental New Drug Application (sNDA) of its oral, once-daily hormonal medication Casodex (bicalutamide 150mg) for the treatment of early stage non-metastatic prostate cancer.
-
- 31 January 2002
- ASTRAZENECA PLC FOURTH QUARTER AND END-OF-YEAR RESULTS 2001 Download the narrative and the figures
-
- 28 January 2002
- ASTRAZENECA SUBMITS NDA IN JAPAN FOR IRESSA (ZD1839) – A NEW CLASS OF ANTI-CANCER TREATMENT AstraZeneca today announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) supporting the use of IRESSA for the treatment of non-small cell lung cancer (NSCLC). IRESSA is the first epidermal growth factor (EGFR) inhibitor to be filed in Japan. This means that the drug is now currently under regulatory review in two major global markets including the US.
-
- 17 January 2002
- ASTRAZENECA OBTAINS REGULATORY APPROVAL FOR ZOLADEX® LA IN JAPAN AstraZeneca announced today that Zoladex® LA (goserelin acetate 10.8mg) for prostate cancer treatment has received marketing approval in Japan. This follows a positive report made by Japan’s Ministry of Health, Labour and Welfare’s (MHLW) Pharmaceutical Affairs Council in December 2001. Zoladex LA (Longer Acting) is the first Luteinizing Hormone-Releasing Hormone analogue (LHRHa) available in Japan with an injection that is effective for three months, and adds to the 3.6mg depot (monthly) formulation,
-
- 15 January 2002
- FDA TO ‘FAST TRACK’ EXTENDED LICENCE APPLICATION FOR ARIMIDEX® IN EARLY BREAST CANCER AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has granted ‘fast track’ status for the supplementary licence application of the Company’s aromatase inhibitor, Arimidex®, for the treatment of post-menopausal women with early breast cancer. This decision follows the exciting first results from the ATAC ( A rimidex, T amoxifen, A lone or in C ombination) study of over 9,300 women, which showed that Arimidex is significantly more effective and has important tolerability
-
- 03 January 2002
- ASTRAZENECA COMPLETES EUROPEAN UNION MUTUAL RECOGNITION PROCEDURE FOR OXIS® TURBUHALER® * AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) on 21 December 2001 for the use of Oxis® Turbuhaler® (formoterol) as a maintenance treatment for asthma in children (6 years and older) in 14 European Union (EU) states. **
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
